InBody Co.,Ltd

KOSDAQ 041830.KQ

InBody Co.,Ltd EPS (Diluted) for the year ending December 31, 2023: USD 2.16

InBody Co.,Ltd EPS (Diluted) is USD 2.16 for the year ending December 31, 2023, a 5.57% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

InBody Co.,Ltd EPS (Diluted) for the year ending December 31, 2022 was USD 2.05, a -6.22% change year over year.
InBody Co.,Ltd EPS (Diluted) for the year ending December 31, 2021 was USD 2.19, a 78.38% change year over year.
InBody Co.,Ltd EPS (Diluted) for the year ending December 31, 2020 was USD 1.23, a -7.15% change year over year.
InBody Co.,Ltd EPS (Diluted) for the year ending December 31, 2019 was USD 1.32, a 1.23% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

KOSDAQ: 041830.KQ

InBody Co.,Ltd

CEO	Dr. Ki-Chul Cha
IPO Date	Dec. 15, 2000
Location	South Korea
Headquarters	InBody Building
Employees	266
Sector	Health Care
Industries Medical Instruments Cosmetics Pharmaceuticals

Description

InBody Co.,Ltd provides body composition analysis solutions worldwide. The company offers body composition analyzers, blood pressure monitors, stadiometers, and body water analyzers, as well as InBody dial and bands. Its products are used in nephrology, liver disease, diabetes, nutrition, and rehabilitation applications. The company was formerly known as Biospace Co., Ltd. InBody Co.,Ltd was founded in 1996 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years